To understand better the role of mast cell secretory products in the genesis of inflammation, a system was developed for in vitro degranulation of human mast cells in skin organ cultures. Within 2 hr after morphine sulfate-induced degranulation, endothelial cells lining microvessels adjacent to affected mast cells expressed an activation antigen important for endothelial-leukocyte adhesion. Identical results were obtained when other mast cell secretagogues (anti-IgE, compound 48/80, and calcium ionophore A23187) were used. Induction of this antigen was abrogated by preincubation with cromolyn sodium, an inhibitor of mast cell secretion, and by antiserum to tumor necrosis factor a. These findings indicate that de-
48/80, and calcium ionophore A23187) were used. Induction of this antigen was abrogated by preincubation with cromolyn sodium, an inhibitor of mast cell secretion, and by antiserum to tumor necrosis factor a. These findings indicate that degranulation of mast cells activates dermal endothelium through tumor necrosis factor-dependent mechanisms. This event may be critical to the elicitation phase of cutaneous inflammation.
Mast cells are resident, granule-containing secretory cells situated about blood vessels of host-environmental interfaces, such as skin and mucosae. Identified more than a century ago by Ehrlich (1) , it has been hypothesized that mast cells play a central role in the genesis and modulation of cellular inflammatory responses (2) (3) (4) . For example, delayed-type hypersensitivity reactions (DHRs) in mice are elicited preferentially at cutaneous sites enriched in mast cells, such as ear and footpad (5) . Moreover, pharmacologic inhibition of release of mast cell secretory products with the cromolyn-like drug proxicromil inhibits the DHR (6) . Similarly, in sensitized guinea pigs, the DHR is abrogated by first purging mast cells at the challenge site with a local injection of the mast cell secretagogue compound 48/80 (7) . Furthermore, mice that are genetically deficient in mast cells (W/W' and S1/Slid) have been reported (4) to exhibit diminished DHR. An unresolved issue in all such studies is whether mast cell degranulation products are capable of primarily triggering leukocytic infiltration of the skin or whether mast cells degranulate secondarily as a result of the inflammatory cascade (8, 9) .
Upon degranulation mast cells release histamine, resulting in gaps between adjacent endothelial cells. This enhances vascular permeability for macromolecules within serum (10) (11) (12) , although it does not always result in inflammatory cell migration into the perivascular compartment (8) . Mast cells also contain heparin, a physiological anticoagulant that influences angiogenesis (13 (16) exclusively on cytokinestimulated or inflamed vascular endothelium. ELAM-1 and related molecules correlate with endothelial activation and with endothelial-dependent mechanisms of neutrophil and mononuclear cell adhesion to the endothelial cell surface in vitro (17, 18) . In organ cultures of human skin, ELAM-1 may be induced only in endothelium of post-capillary venules (19) , the targets of most cutaneous inflammatory reactions. Moreover, expression of ELAM-1 is integral to the evolution of the cutaneous delayed hypersensitivity response (20) . Undefined factors released by skin explants into culture supernatants are capable of inducing ELAM-1 in target monolayers of large-vessel endothelial cells (10) . The recombinant immunoregulatory proteins (cytokines) tumor necrosis factor a (TNF-a) and interleukin 1 (IL-1) elicit endothelial activation and expression of ELAM-1 in vitro (21) (22) (23) . In the skin, IL-1 is produced by epithelial cells, and both IL-1 and TNF-a are produced by monocytes (24) . Although it is likely that these and other endogenous cytokines are responsible for induction of ELAM-1 in vivo, the specific stimuli and cells responsible for their release have not been defined.
To understand the cellular events associated with endogenous mediator release that triggers endothelial activation and endothelial-leukocyte adhesion, we have investigated (25) (19) . Explant viability in this model has been repeatedly assessed by ultrastructure, the ability to induce class II histocompatibility antigens on the surface of target cell types (e.g., endothelial cells) with recombinant interferon y (26) , and the demonstration of continued constitutive endothelial reactivity for anti-factor VIII antibody (19) . In each culture, the medium was supplemented with the indicated mast cell secretagogues, drugs, or antisera. Explants were harvested every 2 hr for 6 hr and at 24 hr and 48 hr, as indicated.
Mast Cell Secretagogues. (16) . It is of the IgGl(K) isotype, and irrelevant isotype-specific controls (e.g., K16/16) do not demonstrate crossreactivity with human foreskin endothelium using these techniques. H4/18 was used in the form of a reconstituted ammonium sulfate precipitate from ascites fluid diluted 1:500. Polyclonal antibodies used in blocking experiments consisted of rabbit anti-human TNF-a (Genzyme) and rabbit anti-human IL-la and (3 (Genzyme). Explants were incubated in anti-TNF-a at 500, 5000, and 50,000 units/ml and in anti-IL-1 at 50, 100, and 200 units/mi. Replicate explants were also incubated in identical concentrations of rabbit serum to exclude nonspecific interference with mast cell mediator effects, and ultrastructure was performed to preclude the possibility that antiserum influenced secretagogueinduced degranulation. Recombinant TNF-a was used, as described (19) , for control ELAM-1 induction in explants.
Immunohistochemistry. For immunohistochemical staining, harvested explants were frozen in OCT compound (Miles Scientific) cooled in liquid nitrogen and stored at -800C.
Frozen specimens were cut in 4-gm cryostat sections, airdried, fixed in acetone, and reacted for 0.5 hr at 370C with the monoclonal antibody H4/18.' Staining was accomplished by a three-step peroxidase-antiperoxidase technique (ref. 27) with 3,3'-diaminobenzidene as the chromogenic substrate. All incubation times were identical, and controls and blocking experiments were evaluated side-by-side with positive samples.
Morphological Studies. Routine transmission electron microscopy consisted of fixation of explants for 24 hr at 40C. Specimens were washed in 0.1 M sodium cacodylate buffer, postfixed in 2% (wt/vol) osmium tetroxide for 1 hr, dehydrated in graded ethanol solutions to propylene oxide, and embedded in Epon. Examination of 1-gm sections (28) stained with toluidine blue and ultrathin sections stained with uranyl acetate and lead citrate was performed using light and transmission electron microscopy, respectively.
RESULTS
Mast Cell Degranulation in Skin Organ Cultures. The ultrastructure of human foreskin explants for the duration of culture (48 hr) was identical to that of noncultured human foreskin, with no evidence of medium or additive-related cytotoxicity. Mast cells in skin explants not exposed to secretagogue exhibited uniformly intact granules. These membrane-bound cytoplasmic granules were round, uniform in -size and shape, and contained homogeneous electrondense matrices (29) (Fig. 1A) . All secretagogues tested produced mast cell degranulation in the skin explant system. MS resulted in widespread degranulation that affected all granules of all mast cells at 5 mmol/liter ( Fig. 1 B and C) ; lower concentrations produced less prominent alterations in a dosedependent manner. Degranulation was characterized by granule enlargement, membrane fusion of adjacent granules and between granule and plasma membranes, and electron lucency of granule matrices (Fig. 1C) . These alterations were similar to those associated with IgE-mediated mast cell degranulation (30) . Calcium ionophore and compound 48/80 resulted in similar granule alterations, although even at high concentrations (100 ,g/ml and 10 mg/ml, respectively), ubiquitous degranulation was not observed. Exposure of explants beyond 45 min did not enhance degranulation for any concentration of secretagogue used. Accordingly, MS was chosen as the principal secretagogue for the subsequent experiments.
Anti-IgE at a maximum dilution of 0.78 mg/ml gave results similar to those obtained using calcium ionophore and compound 48/80. In keeping with previous studies (31) H4/18 antibody reactivity was noted exclusively on endothelial cells lining venules in the superficial dermis in explants exposed for 45 min to MS and then cultured for 2 hr. This induction of ELAM-1 was not observed on any cell type in time-matched cultured explants or in foreskins prior to culture. ELAM-1 expression peaked at 6 hr ( Fig. 1 E and F) , declined by 24 hr, and was absent at 48 hr. These kinetics were identical to those characteristic of ELAM-1 induction by recombinant TNF-a in this organ culture model (19) .
Restriction of immunoreactivity to endothelial cells lining superficial venules has been confirmed by immunoelectron microscopy (19) . Examination of these explants by electron microscopy indicated that ELAM-1 induction was consistently preceded by degranulation of mast cells normally situated about these superficial dermal venules (two to five mast cells per venule). Identical results were obtained using normal adult arm skin in which mast cells were degranulated with MS, indicating that these events were not peculiar to neonatal foreskin. In addition, similar data was also obtained when mast cells of foreskin were degranulated with compound 48/80 (10 mg/ml), calcium ionophore (100 ,tg/ml), or anti-IgE (0.78 mg/ml; Fig. 2 ), demonstrating that ELAM-1 induction was not a result of MS exposure (Fig. 1G) . Calcium ionophore and compound 48/80 produced ELAM-1 staining that was generally less prominent than that associated with MS-induced degranulation. This observation is in keeping with our morphologic observations that compound 48/80 and calcium ionophore are less potent degranulating agents than MS in the organ culture system. Abrogation of ELAM-1 Induction. Incubation of explants with polyclonal blocking antiserum to human TNF-a (500 units/ml), followed by MS-induced degranulation and organ culture (as described above), resulted in abrogation of ELAM-1 induction ( Fig. 1 H and I In summary, this study indicates that mast cell degranulation is linked by cytokine-dependent pathways to induction of ELAM-1 in dermal microvessels (Fig. 3) . These findings help explain the central role of mast cell secretion in the initiation of cutaneous inflammation. As gatekeepers of the microvasculature, mast cells should be critical targets of therapeutic strategies that seek to prevent or ameliorate the earliest phases of the cellular inflammatory cascade.
